Sarepta Preliminary Results: Not What The Market Wanted To Hear [Seeking Alpha]
Sarepta Therapeutics: Is Elevidys A Bust? [Seeking Alpha]
Sarepta Therapeutics (NASDAQ:SRPT) had its price target raised by analysts at Royal Bank Of Canada from $16.00 to $18.00. They now have a "sector perform" rating on the stock.
Sarepta Therapeutics (NASDAQ:SRPT) had its "sell" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues [Yahoo! Finance]